Redmile Group, LLC Buys Clovis Oncology Inc, uniQure NV, Laboratory Corp of America Holdings, Sells AveXis Inc, Puma Biotechnology Inc, Penumbra Inc

• New Purchases: CLVS, QURE, LH, XERS, MOR, ANTM, CTLT, SRRK, ZTS, TCDA,
• Added Positions: IFRX, ARGX, BOLD, DCPH, IMGN, HSKA, ALXN, LIVN, WCG, EHTH,
• Reduced Positions: PEN, ABT, TFX, IRTC, ARRY, SYNH, RGNX, ELGX, NVTA, CNC,
• Sold Out: AVXS, PBYI, PRAH, MDRX, MYL, ARMO, MODN, UHS, PETQ, EXAS,

For the details of Redmile Group, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Redmile+Group%2C+LLC

1. Array BioPharma Inc (ARRY) - 15,978,580 shares, 9.27% of the total portfolio. Shares reduced by 7.23%
2. Amicus Therapeutics Inc (FOLD) - 10,511,732 shares, 5.68% of the total portfolio. Shares reduced by 2.11%
3. Atara Biotherapeutics Inc (ATRA) - 4,126,617 shares, 5.24% of the total portfolio. Shares reduced by 2.58%
4. Immunogen Inc (IMGN) - 12,315,942 shares, 4.14% of the total portfolio. Shares added by 26.94%
5. Xencor Inc (XNCR) - 3,147,043 shares, 4.03% of the total portfolio. Shares reduced by 1.79%

Redmile Group, LLC initiated holding in Clovis Oncology Inc. The purchase prices were between $42.06 and $62.4, with an estimated average price of $48.66. The stock is now traded at around $29.69. The impact to a portfolio due to this purchase was 2.76%. The holding were 1,758,600 shares as of 2018-06-30.

Redmile Group, LLC initiated holding in uniQure NV. The purchase prices were between $21.96 and $39.94, with an estimated average price of $31.97. The stock is now traded at around $35.98. The impact to a portfolio due to this purchase was 2.12%. The holding were 1,624,400 shares as of 2018-06-30.

Redmile Group, LLC initiated holding in Laboratory Corp of America Holdings. The purchase prices were between $160.33 and $189.41, with an estimated average price of $175.63. The stock is now traded at around $170.76. The impact to a portfolio due to this purchase was 1.79%. The holding were 288,400 shares as of 2018-06-30.

Redmile Group, LLC initiated holding in Xeris Pharmaceuticals Inc. The purchase prices were between $18.8 and $20.22, with an estimated average price of $19.43. The stock is now traded at around $18.21. The impact to a portfolio due to this purchase was 1.58%. The holding were 2,412,642 shares as of 2018-06-30.

Redmile Group, LLC initiated holding in MorphoSys AG. The purchase prices were between $25.15 and $30.6, with an estimated average price of $27.48. The stock is now traded at around $26.64. The impact to a portfolio due to this purchase was 1.33%. The holding were 1,269,800 shares as of 2018-06-30.

Redmile Group, LLC initiated holding in Anthem Inc. The purchase prices were between $220.13 and $245.16, with an estimated average price of $231.73. The stock is now traded at around $271.64. The impact to a portfolio due to this purchase was 1.2%. The holding were 146,000 shares as of 2018-06-30.

Redmile Group, LLC added to a holding in InflaRx NV by 138.24%. The purchase prices were between $27.33 and $41.46, with an estimated average price of $34.55. The stock is now traded at around $34.47. The impact to a portfolio due to this purchase was 1.31%. The holding were 2,027,700 shares as of 2018-06-30.

Redmile Group, LLC added to a holding in argenx SE by 182.19%. The purchase prices were between $74.84 and $100.16, with an estimated average price of $89.3. The stock is now traded at around $76.20. The impact to a portfolio due to this purchase was 1.25%. The holding were 673,300 shares as of 2018-06-30.

Redmile Group, LLC added to a holding in Audentes Therapeutics Inc by 70.32%. The purchase prices were between $28.04 and $42.81, with an estimated average price of $37.02. The stock is now traded at around $38.33. The impact to a portfolio due to this purchase was 1.21%. The holding were 2,228,656 shares as of 2018-06-30.

Redmile Group, LLC added to a holding in Deciphera Pharmaceuticals Inc by 79.85%. The purchase prices were between $20.06 and $44.95, with an estimated average price of $29.49. The stock is now traded at around $38.49. The impact to a portfolio due to this purchase was 0.89%. The holding were 1,477,080 shares as of 2018-06-30.

Redmile Group, LLC added to a holding in Immunogen Inc by 26.94%. The purchase prices were between $9.52 and $12.15, with an estimated average price of $10.53. The stock is now traded at around $9.64. The impact to a portfolio due to this purchase was 0.88%. The holding were 12,315,942 shares as of 2018-06-30.

Redmile Group, LLC added to a holding in Heska Corp by 48.79%. The purchase prices were between $74.5 and $108.91, with an estimated average price of $93.39. The stock is now traded at around $109.97. The impact to a portfolio due to this purchase was 0.42%. The holding were 354,776 shares as of 2018-06-30.

Redmile Group, LLC sold out a holding in AveXis Inc. The sale prices were between $115.91 and $217.83, with an estimated average price of $198.8.

Redmile Group, LLC sold out a holding in Puma Biotechnology Inc. The sale prices were between $48.3 and $68.25, with an estimated average price of $57.86.

Redmile Group, LLC sold out a holding in PRA Health Sciences Inc. The sale prices were between $79.95 and $96.22, with an estimated average price of $86.13.

Redmile Group, LLC sold out a holding in Allscripts Healthcare Solutions Inc. The sale prices were between $11.52 and $12.86, with an estimated average price of $12.32.

Redmile Group, LLC sold out a holding in Mylan NV. The sale prices were between $35.37 and $41.86, with an estimated average price of $39.24.

Redmile Group, LLC sold out a holding in ARMO BioSciences Inc. The sale prices were between $25.68 and $50.05, with an estimated average price of $41.01.

Redmile Group, LLC reduced to a holding in Penumbra Inc by 86.81%. The sale prices were between $112.2 and $165.95, with an estimated average price of $142.06. The stock is now traded at around $149.15. The impact to a portfolio due to this sale was -2.16%. Redmile Group, LLC still held 72,170 shares as of 2018-06-30.

Redmile Group, LLC reduced to a holding in Abbott Laboratories by 59.01%. The sale prices were between $57.57 and $63.54, with an estimated average price of $60.61. The stock is now traded at around $73.02. The impact to a portfolio due to this sale was -1.52%. Redmile Group, LLC still held 449,300 shares as of 2018-06-30.

Redmile Group, LLC reduced to a holding in Teleflex Inc by 54.76%. The sale prices were between $246.68 and $284.87, with an estimated average price of $268.03. The stock is now traded at around $265.26. The impact to a portfolio due to this sale was -0.97%. Redmile Group, LLC still held 79,886 shares as of 2018-06-30.

Redmile Group, LLC reduced to a holding in iRhythm Technologies Inc by 45.02%. The sale prices were between $57.89 and $84.41, with an estimated average price of $69.82. The stock is now traded at around $94.89. The impact to a portfolio due to this sale was -0.81%. Redmile Group, LLC still held 401,303 shares as of 2018-06-30.

Redmile Group, LLC reduced to a holding in Syneos Health Inc by 35.67%. The sale prices were between $35 and $48.9, with an estimated average price of $41.37. The stock is now traded at around $51.00. The impact to a portfolio due to this sale was -0.76%. Redmile Group, LLC still held 981,673 shares as of 2018-06-30.